2026-11-06 15:00 ET: Healthcare label / residual split after Thu SM crush — cluster-5 pharma flat, TMO tools bounce, MRNA BMO ~+10% overrun (not automatic read-through); REGN singleton

Slot: Fri 2026-11-06 15:00 ET hourly research. Status: written ~15:05–15:25 ET (EST); whiggity folded in follow-up ~15:30+ ET (budget exhausted after 4 rounds; MRNA leg only). Screening/research, not investment advice. No rule is implemented by this report.

Actionable for today's (Fri Nov 6) trading: NO. The live-rule entry window was 10:00 AM EST (60-minute time stop → ~11:00). Afternoon tape under STRESS (VIX still >22) with short_momentum suspended is descriptive only — not a validated fade, bounce, SM reactivation, or MRNA peer inheritance. Weekend / Mon prep remains the 11:00 gap stack (TTD/KKR/HIMS/OXY/MARA/BRK + CEG BMO). HIMS appears here only as Mon-AMC handoff context — do not re-litigate S-145.

1. Incremental focus (rotate from 09:00–14:00)

Prior Fri hours covered VST/MRNA/CEG (09:00, 10:00), the Mon gap stack (11:00), industrials HON/UNP/GEV/ETN (S-146, 12:00), staples/tobacco PM (S-147, 13:00), and memory/storage MU/WDC/STX (S-148, 14:00).

This hour rotates to the healthcare residual / label split after Thursday’s SM healthcare crush + today’s MRNA BMO afternoon path:

1. Cluster 5 pharma — ABBV, AMGN, BMY, GILD, JNJ, LLY, NVO, PFE, VRTX (avg ρ 0.633); SM Healthcare ×5 residuals on 8:58 run: REGN/PFE/LLY/GILD/VRTX (note REGN is flagged Healthcare ×5 but lives in cluster 38 singleton on correlations).
2. REGN — correlation cluster 38 singleton; Thu −2.98%; Fri soft green.
3. TMO — life-science tools singleton (cluster 48); MR fade-long on 8:58; Thu −4.14%; Fri afternoon bounce ~+2.3%.
4. MRNA — cluster 20 with MRK (avg ρ 0.754); BMO today; Fri ~+10% vs hist avg |gap| 3.28% (overrun).
5. HIMS — Mon 11-09 AMC handoff only (cluster 16 with AFRM/SOFI); already in 11:00 / S-145 — not re-argued here.

2. Live TRAI evidence and clock audit

Read-only API checks returned HTTP 200 around drafting (~15:05–15:10 ET). Linked endpoints are mutable. Sources: latest, events, correlations, regime, scorecard, macro.

Scorecard constraint [TRAI]: live-rule 10:00 AM EST entry, 1 ATR stop / 2 ATR target, 60-minute time stop. Do not claim new live-rule edge. Afternoon paths are descriptive only.

Yahoo afternoon path (~15:09 ET vs Thu close)

Takeaway: Under Friday afternoon SPY/QQQ green + VIX still >22, MRNA ripped on its own BMO, TMO bounced as tools/MR, and cluster-5 large pharma stayed roughly flat-to-soft (PFE still red). That is a within-healthcare product / correlation split — not one "Healthcare" residual book. MRNA ≠ automatic read-through to cluster-5 SM residuals (see §4–5).

3. Correlation structure vs sector / press labels [TRAI + S-001]

60-day clusters (/api/correlations, asOf 2026-11-05). Matrix values stored as ρ×100 → report as 0.xx:

Label error: SM clusterFlag "Healthcare ×5" groups REGN with PFE/LLY/GILD/VRTX even though REGN is a correlation singleton and MRNA/TMO sit elsewhere. Fading or chasing "healthcare" as one residual book after a stress crush is the same class of error as industrials S-146, staples S-147, and memory/storage S-148. Proposed S-149 below.

4. Business facts and primary catalysts (with citations)

MRNA — Moderna (mRNA vaccines / therapeutics) — BMO today [V-P]

• Primary: Moderna Q3 2026 via Newswire, 2026-11-06 (Newswire HTTP 200 this hour). Condensed figures verified from release text/tables:
• Total revenue $1.313B (+29% YoY vs $1.016B); US $780M / intl $533M; net product sales $1.273B.
• Net income $162M; diluted EPS $0.38 (vs loss $0.51 YoY).
• FY26 revenue growth raised to 15%–25% (was up to 10%); R&D ~$2.7B (was ~$2.9B); YE cash/investments $8.1–$8.3B (was $4.7–$5.2B) including ~$2.6B net convertible proceeds.
• mFLUSIVA FDA approval (5th product); intismeran Ph3 with Keytruda (HR 0.58 recurrence/death); norovirus Ph3 interim missed early-success criteria.
• IR / filing timing: Prefer Newswire [V-P] above. Working IR hub: quarterly-results (HTTP 200 this fold). Secondary 8-K mirror (StockTitan MRNA 8-K) shows EDGAR accepted Fri 2026-11-06 06:47 AM EST — nuance vs draft "BMO" label: document acceptance was pre-open; call was scheduled 8:00 AM ET (issuer). Specific Q3 news-details deep link tried earlier returned 404 from this box. CNBC summary also covers beat/raise (CNBC, 2026-11-06) [S].
• Cash-guide nuance (F5): YE cash raise to $8.1–$8.3B coincides with Sept convert ~$3.0B principal / ~$2.6B net — do not treat the cash-guide raise as pure ops (already in Newswire text; reinforce).
• GSK patent cross-license (F10, NEW): same Newswire / 8-K exhibit — Moderna–GSK settle (agreement dated 2026-10-28); patent cross-licenses in infectious disease; "no payments" of any kind on those licenses [V-P via Newswire]. Not previously called out in this report body.
• Afternoon path: Yahoo ~15:09 ~+9.97% vs Thu 241.46 — overruns TRAI hist avg |gap| 3.28% (~3×). Framing under S-006 / S-143 / S-141: do not fade huge positive overrun same-day; do not reactivate SM; MRNA ≠ automatic read-through to cluster-5 residuals (issuer growth primarily intl COVID + pipeline — PFE clearest overlap hypothesis only, ρ 0.45). Auditor open: is the ~+9–10% vs 3.3% hist |gap| look-ahead-safe given 06:47 acceptance vs 08:58 premarket run? Log only — afternoon path still descriptive; Actionable Fri NO.

Cluster-5 large pharma — Thu crush drivers [S / unknown]

• No verified company-specific Thu earnings 8-K explaining the crush for LLY/GILD/PFE/VRTX/AMGN/ABBV on 2026-11-05. Treat driver as unknown / secondary:
• LLY: TradingKey-style narrative — valuation / profit-taking / sector flows (TradingKey LLY, 2026-11-05) [S].
• GILD: post-earnings consolidation / profit-taking (TradingKey GILD, 2026-11-05) [S].
• PFE: MarketBeat notes −2.9% session after recent raise — not a new Thu print (MarketBeat PFE, 2026-11-05) [S].
• Prior primary prints (already digested; not Thu news): PFE 11-03 BMO raise; LLY 10-29 BMO raise; GILD 10-29 AMC beat-and-raise; VRTX 11-02 AMC in-line/raise — see company notes.

REGN — Regeneron (singleton) [S on Eylea narrative]

• Last primary print: Q3 2026-10-30 BMO beat + Sanofi expansion (Regeneron IR) — already in REGN.md.
• Eylea HD competition is older Q3-call context, not a new Thu 8-K. Secondary: Trefis, 2026-11-05 recycles Oct 30 call biosimilar/pricing commentary [S]. Do not invent a Thu company-specific catalyst.
• Fri ~+0.7% soft reclaim; still SM Healthcare ×5 residual (suspended).

TMO — Thermo Fisher (tools singleton / MR fade)

• Last primary print: Q3 2026-10-21 (TMO IR).
• On 8:58 run as MR fade-long under STRESS (feeds S-144). Thu −4.14%; Fri afternoon ~+2.3% bounce — descriptive only; live-rule window closed. Weak ρ to large pharma (≤0.34) supports tools-vs-pharma split (S-149).

HIMS — Mon AMC handoff only

• See 11:00 report / S-145. Fri ~+8% bounce does not clear Mon overnight gap-risk. Not part of cluster-5 / S-149 pharma residual test.

5. Post-catalyst / gap behavior (TRAI events + priors)

Aggregate TRAI earnings stats (unchanged philosophy): big |gap| continuation ~50%; do not add drift premium (S-005). Huge positive MRNA overrun → S-006 ban on same-day fade; no SM reactivation (S-141).

6. Why MRNA is not cluster-5 read-through [S-001 / S-014]

1. Different correlation home: cluster 20 (MRK) vs cluster 5 large pharma; MRNA–PFE ρ only 0.45, MRNA–LLY 0.38.
2. Different catalyst: own BMO beat-and-raise with intl COVID + pipeline — not a shared residualZ event with REGN/PFE/LLY/GILD/VRTX.
3. Tape: XBI ~+2.5% while XLV ~flat and cluster-5 names ~0% — biotech/print bid ≠ large-pharma residual fade.
4. Policy: SM Healthcare ×5 remains suspended; afternoon MRNA strength is not reactivation evidence.

7. Whiggity consult

Consult: succeeded after the initial push. Chat: whiggity conv e0c84ccc…. Whiggity reported tool budget exhausted after 4 rounds; only the MRNA leg opened (2 searches + 2 link-readers). Non-MRNA draft items left [UNV] by whiggity. Folded below: keep only points we independently verify; rest stay open / [UNV]. Still Actionable Fri NO.

Kept after verification

Secondary / open (whiggity-attributed; conflicts)

• Cash-guide vs convert (F5): YE cash raise coincides with convert proceeds — do not treat as pure ops (reinforced in §4).
• BMO vs 06:47 EST acceptance (F3): timing nuance logged; call time known (8:00 AM ET issuer), acceptance earlier.
• Auditor handoff — overrun look-ahead: ~+9–10% vs hist |gap| 3.3% — is the afternoon path look-ahead-safe given 06:47 acceptance vs 08:58 premarket run? Open question; afternoon path still descriptive only; Actionable Fri stays NO.
• Non-MRNA draft items: left [UNV] by whiggity (budget); we did not invent fills — Thu crush still unknown/secondary as in §4.
• Hypotheses H1–H5: budget cut off after MRNA leg; no separate H-text captured beyond auditor overrun / S-149 framing. Park useful bits as S-149 companion enrichments (§8) rather than new S-numbers.

Rejected

None this hour (no opaque F10-style reject; F10 GSK verified via Newswire).

8. Strategy proposals (for 6 PM refinement — not live)

S-149: Split TRAI "Healthcare" SM/MR risk into cluster-5 pharma vs REGN singleton vs TMO tools vs MRNA/MRK print cluster · PROPOSAL (extends S-001 / S-014 / S-146 / S-147 / S-148)

• Rule (proposal): when clusterFlag or sector label is Healthcare, do not count cluster-5 large pharma (PFE/LLY/GILD/VRTX/AMGN/ABBV/…), REGN (cluster 38 singleton), TMO (cluster 48 tools singleton), and MRNA/MRK (cluster 20) as one correlated residual book. Cap exposure using 60d correlation clusters; optional hand map: large-pharma core (cluster 5), Regeneron singleton, life-science tools (TMO), mRNA/print pair (MRNA–MRK), fintech-adjacent telehealth (HIMS cluster 16 — separate calendar risk).
• Companion tests: (1) after a same-day healthcare SM crush under VIX>22, measure next-session cluster-5 mean vs REGN vs TMO vs MRNA return spreads; (2) on MRNA (or peer) BMO overrun days (|gap| ≥ 2× hist avg), test whether cluster-5 residuals co-move with MRNA or decouple (hypothesis: decouple); (3) look-ahead hygiene on overrun tags — require EDGAR/wire acceptance timestamp ≤ live-rule clock (today: 06:47 EST acceptance vs 08:58 premarket run; afternoon ~+10% still descriptive only). Costs, day clustering, OOS, multiple-testing caution. Whiggity H1–H5 not separately numbered — budget cut after MRNA leg.
• Why (live case): Fri 2026-11-06 ~15:09 — MRNA ~+10%, TMO ~+2.3%, cluster-5 roughly flat (PFE still soft), REGN soft green after Thu crush; SM still tags Healthcare ×5 including REGN singleton.
• Evidence: this report §2–6, §8.

Evidence adds

• S-001 / S-014: Healthcare sector / Healthcare ×5 flag over-aggregates; afternoon path splits cluster-5 vs TMO tools vs MRNA print vs REGN singleton.
• S-006 / S-143: MRNA ~+10% positive overrun after BMO beat/raise — do not same-day fade; do not treat as peer inheritance into suspended SM residuals. Filing accepted 06:47 EST (mirror) before 08:58 run — look-ahead open for auditor (§7).
• S-141 / SM policy: do not reactivate short momentum on Healthcare ×5 after Fri flat/bounce paths.
• S-144: TMO/AMGN remain on MR fade-long list under STRESS + inversion (afternoon VIX9D/VIX ~1.06); TMO bounce is descriptive only after 10:00 window — NEEDS DATA unchanged.
• S-145: HIMS Mon AMC unchanged — not re-litigated; Fri HIMS bounce ≠ cleared overnight risk.
• S-005: no day-1 LM claim on MRNA overrun; LM bucket empty.
• MRNA balance-sheet / legal (whiggity fold): YE cash raise includes convert proceeds (not pure ops); GSK patent cross-license settle "no payments" (2026-10-28) now cited from Newswire [V-P] — fundamental, not a live-rule signal.

9. Open questions

1. Quantitative share of Thu’s healthcare crush explained by broad SPY −4.4% / vol vs idiosyncratic residual (needs event study; not done here). Whiggity non-MRNA leg [UNV] / budget-cut.
2. Whether SM Healthcare ×5 should drop REGN when correlations place it in a singleton (engine/display issue for S-149).
3. Persistence of MRNA vs cluster-5 divergence into Mon 11-09 (pre mega-gap night) and into MRNA Analyst Day Nov 12 (issuer calendar on Newswire).
4. Auditor look-ahead: is MRNA ~+9–10% overrun vs hist 3.3% |gap| tagged safely given 06:47 EST 8-K acceptance vs 08:58 premarket run? Afternoon path remains descriptive; Actionable Fri NO.
5. Whiggity H1–H5 full text not captured past MRNA leg — enrich S-149 companions only (§8); no new S-numbers this fold.

10. Sources (selected)

• TRAI APIs as linked in §2 (read ~15:05–15:10 ET).
• Yahoo Finance chart API daily (unofficial, may be delayed) — Thu closes and Fri ~15:09 prints.
• Moderna Q3 2026 Newswire, 2026-11-06 [V-P] — includes GSK settle / convert / cash guide.
• Moderna IR quarterly-results [V-2 hub, HTTP 200].
• StockTitan MRNA 8-K mirror [S-1] — EDGAR accepted 2026-11-06 06:47 AM EST (EDGAR primary not opened).
• CNBC Moderna Q3, 2026-11-06 [S].
• Whiggity consult (MRNA-only leg; budget after 4 rounds): conv e0c84ccc….
• TradingKey LLY, 2026-11-05 [S].
• TradingKey GILD, 2026-11-05 [S].
• MarketBeat PFE, 2026-11-05 [S].
• Trefis REGN Eylea context, 2026-11-05 [S — older call narrative, not Thu 8-K].
• TMO Q3 IR, 2026-10-21 [V-P prior].